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A B S T R A C T
Background: Following radical nephro-ureterectomy for urothelial carcinoma of the upper urinary tract (UUT),
the reported bladder recurrence rate of urothelial carcinoma is 22–47%. A single intravesical instillation of
chemotherapy within 10 days following nephro-ureterectomy has the potential to decrease the risk of a bladder
recurrence signiﬁcantly. Despite recommendation by the European Association of Urology guideline to ad-
minister a single instillation postoperatively, the compliance rate is low because the risk of extravasation of
chemotherapy.
Aim: To reduce the risk of bladder cancer recurrence by a single intravesical instillation of Mitomycin im-
mediately (within 3 h) before radical nephro-ureterectomy or partial ureterectomy.
Methods: Adult patients (age≥ 18 years) with a (suspicion of a) urothelial carcinoma of the UUT undergoing
radical nephro-ureterectomy or partial ureterectomy will be eligible and will receive a single intravesical in-
stillation of Mitomycin within 3 h before surgery. In total, 170 patients will be included in this prospective,
observational study. Follow-up will be according to current guidelines.
Results: The primary endpoint is the bladder cancer recurrence rate up to two years after surgery. Secondary
endpoints are: a) the compliance rate; b) oncological outcome; c) possible side-eﬀects; d) the quality of life; e)
the calculation of costs of a single neoadjuvant instillation with Mitomycin and f) molecular characterization of
UUT tumors and intravesical recurrences.
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Conclusions: A single intravesical instillation of Mitomycin before radical nephro-ureterectomy or partial ur-
eterectomy may reduce the risk of a bladder recurrence in patients treated for UUT urothelial carcinoma and will
circumvent the disadvantages of current therapy.
1. Introduction
Urothelial carcinoma of the upper urinary tract (UUT) is a relatively
rare disease with an incidence of 2 per 100.000 person/year in Europe
[1]. At diagnosis 60% of UUT tumors are invasive versus only 15–25%
for urothelial carcinoma of the bladder [2,3]. The outcome of UUT
urothelial cancer is rather poor: the 5-year survival rate following ra-
dical nephro-ureterectomy (RNU) varies from less than 50% for pa-
thological stage pT2 or pT3 disease versus less than 10% for pT4 disease
[3]. The characteristics of high-risk UUT disease are: high-grade tumor
at biopsy, multifocalitiy, positive urinary cytology, transmural disease,
hydro-nephrosis on imaging and a tumor size ≥1 cm [4–6]. For high-
risk urothelial carcinoma of the UUT, RNU with excision of the ipsi-
lateral bladder cuﬀ is the treatment of choice, either by open or mini-
mally invasive surgery [2].
Despite this radical surgical procedure, the bladder recurrence rate
at two years following RNU for UUT urothelial carcinoma varies from
22 to 47% [4,7–9]. A recent study showed that 70% of these re-
currences occurred in the ﬁrst year following RNU [10]. Risk factors for
a bladder recurrence following RNU are previous bladder cancer, tumor
multiplicity, tumor location, tumor stage, and the operative modality
[7,11]. For the prediction of intravesical recurrences following RNU,
two studies designed predictive tools with an accuracy of 62%–69%.
This indicates the diﬃculties in predicting which patients will develop
subsequent bladder recurrences [11,12].
Recently, two randomized controlled trials have shown that a
postoperative intravesical instillation of chemotherapy reduced the risk
of a bladder recurrence following RNU [8,9]. A meta-analysis of these
two studies showed that an intravesical instillation with chemotherapy
within 10 days following RNU decreased the risk of bladder recurrence
with 52%; the absolute risk reduction was 13% [10]. Despite the fact
that the European Association of Urology (EAU) guideline recommends
a single postoperative intravesical instillation with chemotherapy based
on the result of these two studies [2], the compliance rate in clinical
practice to this additional treatment is low. A survey among Dutch
urologists showed that only 10% actually administers a postoperative
instillation [10]. This reluctance is mainly due to the fact that a fresh
wound is present in the bladder, which could lead to extravesical
leakage of chemotherapy and with that potential life-threatening se-
quelae [13].
Here, we present the REBACARE study, in which patients receive a
single intravesical instillation with chemotherapy just before RNU or
partial ureterectomy for an UUT urothelial carcinoma. As subsequent
bladder recurrences probably result from intraluminal seeding and the
implantation of cancer cells [14,15], a preoperative instillation with
chemotherapy could eradicate possible seeding of cancer cells in the
bladder. This neoadjuvant strategy has previously been shown to be
eﬀective in the treatment of non-muscle invasive bladder cancer using
device-assisted instillations of Mitomycin [16]. The approach of a single
instillation with chemotherapy before surgery has the following ad-
vantages: i) it will circumvent the possibility of extravesical leakage of
chemotherapy; ii) it will spare the patient an invasive diagnostic pro-
cedure (cystogram); and iii) it could result in a better compliance of
urologists.
2. Study design
2.1. Study management
The REBACARE study is designed as a multicenter, prospective,
non-randomized cohort study in a clinical setting. Inclusion of patients
will take place from September 2017 till December 2019. The estimated
end of the study is December 2021, two years following RNU or partial
ureterectomy of the last included patient. The follow-up will be in ac-
cordance with the ‘EAU guideline for the treatment of upper urinary
tract urothelial carcinoma’ in which the surveillance regimen consists of
cystoscopy, urinary cytology, and CT urography scans [2]. Only bladder
recurrences (urothelial carcinoma) within two years following surgery
will be counted for study purposes. In case a bladder recurrence is
suspected, a diagnostic biopsy is warranted to histologically conﬁrm a
urothelial carcinoma of the bladder (Appendix A for the ﬂow-chart of
the trial).
The relapse rate in the study cohort will be compared with the re-
lapse rate of a matched historical cohort. This historical cohort will
consist of patients older than 18 years who underwent a RNU or partial
ureterectomy for urothelial carcinoma of the UUT, performed between
2001 and 2015 in the participating centers, received no perioperative
intravesical instillation of chemotherapy and who had no previous
history of a urothelial carcinoma of the bladder.
2.2. Population
Adult patients (age ≥18 years) who undergo a RNU or partial ur-
eterectomy (open or laparoscopic) for a primary urothelial carcinoma
of the UUT will be eligible. These patients will be selected from parti-
cipating centers in the Netherlands. Approximately 150 RNU's for ur-
othelial carcinoma of the UUT were performed yearly in the
Netherlands between 2006 and 2010.
No exact information is available for the total number of partial
ureterectomy procedures performed in the Netherlands for UUT ur-
othelial carcinoma. However, probably, these numbers are increasing
due to the growing elderly population who are diagnosed with UUT but
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are too frail to undergo a RNU or have impaired renal function.
Moreover, evidence is emerging that partial ureterectomy is feasible not
only for an imperative indication, such as patients having a solitary
kidney [17]. Given this increase in the number of partial ureterectomies
performed, it is estimated that at least 90 patients per year can be in-
cluded in the present study, whereby this number includes both patients
undergoing RNU or partial ureterectomy.
See Appendix B for full inclusion and exclusion criteria of the study.
2.3. Study objectives
2.3.1. Primary objective
To demonstrate that a single intravesical instillation of che-
motherapy immediately (within 3 h) before RNU or partial ureter-
ectomy for urothelial carcinoma of the UUT reduces the risk of a sub-
sequent urothelial bladder cancer recurrence up to two years after
surgery with 40% (from 22-47% to 13.2–28.2%) compared to a mat-
ched historical cohort who received no perioperative intravesical in-
stillation.
2.3.1.1. Index objective: risk reduction. A trial by O'Brien et al.
randomized 144 patients to receive Mitomycin 40mg at the time of
urethral catheter removal following RNU (median time 7 days) and 140
patients to receive standard of care [9]. In the Mitomycin arm, 105 of
144 patients (73%) and 115 of 140 patients (82%) in the standard of
care arm received their allocated treatment. Thirteen of 105 patients
who received Mitomycin and 20 of 115 patients allocated to standard of
care treatment did not complete follow up. By modiﬁed intention-to-
treat analysis, 21 of 120 patients (17%) in the Mitomycin arm
developed a bladder recurrence in the ﬁrst year versus 32 of 119
patients (27%) in the standard of care arm (p=0.055). By treatment as
per protocol analysis, 17 of 105 patients (16%) in the Mitomycin arm
and 31 of 115 patients (27%) in the standard treatment arm developed
a bladder recurrence (p=0.03). This resulted in a relative risk
reduction in the recurrence rate in the ﬁrst year following RNU of
almost 40%; the absolute risk reduction was 11%. Ito et al. evaluated
the eﬃcacy of a single early intravesical instillation of Pirarubicin
within 48 h following RNU in the prevention of bladder recurrence [8].
In this smaller study, 36 patients were included in both the intervention
and control arm. Signiﬁcantly fewer patients in the Pirarubicin group
compared to the control group had a bladder recurrence at 2 years
following surgery (16.9% in the intervention vs. 42.2% in the control
group). Consequently, this resulted in a considerable higher relative
risk reduction as shown by O'Brien et al. (Ito et al. Odds ratio (OR)
0.280; 95% Conﬁdence Interval (CI): 0.093–0.831, p=0.023 vs.
O'Brien et al. OR 0.577; 95% CI 0.310–1.073, p=0.82) [10]. It's
possible that they achieved a higher reduction in recurrence due to the
administration of chemotherapy within 48 h instead of within 10 days
after surgery.
In addition a single instillation of chemotherapy following trans-
urethral resection of bladder tumors (TURBT) for low- and inter-
mediate-risk urothelial carcinoma of the bladder (UCB) induces a re-
lative risk reduction of 40% to prevent a subsequent bladder tumor
recurrence [18–20]. To prevent the implantation of tumor cells, the
instillation should be given as soon as possible following TURB. In all
studies which examined the eﬀectiveness of a single, immediate, post-
operative, intravesical instillation of chemotherapy following TURB,
the instillation was given within 24 h following surgery [21]. This
postoperative instillation following TURBT is most eﬀective when ad-
ministered within few hours of surgery [22].
2.3.2. Secondary objectives
a) To show a ≥80% compliance rate and accurate and consistent
protocol performance of a single neoadjuvant instillation with MMC
3 h before RNU or partial ureterectomy for a urothelial carcinoma of
the UUT.
b) To assess the 2-year overall, cancer-speciﬁc and recurrence-free
survival of a single neoadjuvant instillation with MMC before RNU
or partial ureterectomy for UUT urothelial carcinoma compared
with no perioperative intravesical instillations.
c) The toxicity of the regime as assessed by the CTCAE.
d) The impact on the quality of life of the subjects when receiving a
neoadjuvant instillation with Mitomycin.
e) Costs from a societal perspective using a time horizon of two years
and incremental cost-eﬀectiveness ratios.
f) A molecular characterization of the UUT urothelial carcinoma and
subsequent (recurrent) urothelial carcinoma of the bladder (side-
study).
2.3.2.1. Index objective: compliance rate. Despite level I evidence
showing that a postoperative instillation with chemotherapy
following RNU decreases the risk of a subsequent bladder recurrence,
which is also recommended by the EAU guideline (Level B evidence)
[2], the compliance rate is low in current clinical practice. A Dutch
survey showed a compliance rate of less than 10% [10]. Therefore, by
conducting this trial, we aim to show not only that a neoadjuvant
instillation of chemotherapy is equally eﬀective as a postoperative
instillation in reducing the risk of a subsequent bladder cancer
recurrence, but it must also lead to a much higher compliance rate of
clinicians to this neoadjuvant strategy because it lacks the potential risk
of extravesical extravasation of chemotherapy.
2.3.2.2. Index objective: survival rates. At the time of diagnosis, 60% of
all urothelial carcinomas of the UUT are invasive resulting in overall
poor survival rates for patients with urothelial carcinoma of the UUT. In
a large retrospective study by Adibi et al., the 5-year survival rates
among 1462 patients who underwent RNU were less than 50% for stage
pT2 or pT3 disease and less than 10% for pT4 disease [23].
Several studies have assessed individual patient risk factors for
oncologic outcomes [5,7,12,24,25]. Lughezzani et al. and Mathieu et al.
identiﬁed tumor stage and grade to be the most signiﬁcant factors in
oncological outcome [5,26]. Moreover, with respect to surgery, cancer-
free surgical margins and the method of bladder cuﬀ resection (trans- or
extravesically) had the most signiﬁcant impact on cancer-speciﬁc sur-
vival and overall survival. The most signiﬁcant risk factors for in-
travesical recurrence of a urothelial cell carcinoma post RNU were a
previous history of a urothelial cell carcinoma of the bladder and
multifocality of the UUT tumor [25].
In the present study, the 2-years survival rates post RNU and partial
ureterectomy will be assessed and stratiﬁed by individual patient
characteristics. The technique of bladder cuﬀ resection is mandatory,
including a trans- or extravesical approach, and uniformly performed in
all study participants. A secondary aim of this study is to develop a
novel predictive model for clinical outcome (bladder cancer recurrence
and survival) following RNU for urothelial carcinoma of the UUT.
Predictive nomograms are used widely in urology to help patients
counseling and complex decision-making regarding treatment, but none
of these to date have been developed based on prospective data and
none have achieved widespread routine use, due to low level of evi-
dence and lack of external validation. In a meta-analysis by Mbeutcha
et al. on predictive models for the treatment of urothelial carcinoma of
the UUT [24], a positive predictive value of 89% was achieved when
T. van Doeveren et al. Contemporary Clinical Trials Communications 9 (2018) 121–129
123
combining hydronephrosis, ureteroscopic grade and urinary cytology
for prediction of advanced-stage of UUT urothelial carcinoma [6]. If all
three were negative, the negative predictive value was 100%. Xylinas
et al. acquired an accuracy of 69% for postoperative prediction of in-
travesical recurrence risk at 2 years [11]. They combined age, gender,
history of bladder cancer, tumor location, clinical stage, concomitant
carcinoma in situ (CIS), lymph node metastasis, bladder-cuﬀ excision
and surgical approach.
2.3.2.3. Index objective: toxicity. Moriarity et al. reported on the safety
of an intravesical instillation with MMC or Adriamycin that was
administered during RNU in 51 patients. Through a two-way
catheter, inserted at the beginning of the procedure, MMC (40mg) or
Adriamycin (40mg) was instilled. The catheter was clamped for one to
2 h (median time 60min, range 45–120min). Just before the bladder
was opened for the resection of the ureteric oriﬁce, the chemotherapy
was drained passively and the bladder was occasionally irrigated with
saline. In total 31 of the 51 RNU's were performed by an extravesical
excision of the bladder cuﬀ. The other techniques consisted of
intravesical excision of the bladder cuﬀ or intramural ureterectomy.
Nine out of 51 patients underwent a distal ureterectomy only. The intra-
and postoperative complications were monitored up to 90 days
following surgery. No adverse events were reported that were
attributable to MMC or Adriamycin instillation [27]. Furthermore, in
the studies on the eﬃcacy of a single instillation of post-operative
intravesical chemotherapy by O'Brien et al. and Ito et al. only non-
serious adverse events were reported [8,9].
Although the reported toxicity is acceptable it is important to re-
cognize and monitor possible side-eﬀects attributable to the MMC in-
stillation. To manifest possible adverse events the toxicity will be as-
sessed in the present study until 3 months following surgery by the
National Cancer Institute Common Toxicity Criteria (CTCAE) version
4.0. These toxicity criteria consist of standardized deﬁnitions for ad-
verse events that describe the severity of organ toxicity for patients
receiving cancer therapy.
2.3.2.4. Index objective: quality of life. It is hypothesized that a
neoadjuvant instillation with Mitomycin will not have a negative
impact on the quality of life. To address this hypothesis, all patients
will have to complete two questionnaires at inclusion (T0), before
surgery (with neo-adjuvant treatment), and at two weeks (T2) and three
months (T3) following surgery. The EQ5D-5L, a standardized patient-
reported instrument to measure general health, and the EORTC QLQ-
C30, a questionnaire to assess the quality of life of cancer patients will
be used. Both are validated questionnaires for measuring the quality of
life within patients suﬀering from cancer. All time points (T0, T2 and
T3) coincide with regular visits to the outpatient department in order to
limit the extra burden for participating patients. To be able to
adequately address the quality of life end point of the study, the
dropout rate for completed questionnaires must be less than 10%.
2.3.2.5. Index objective: costs. The costs consist of direct costs (e.g.,
single gift of Mitomycin, personnel costs of health professionals
involved, disorder related medication, disorder related innervations,
time duration of hospital, informal care) and indirect costs
(productivity loss) associated with each regimen. The economic
evaluation will be a cost-utility analysis and a cost-eﬀectiveness
analysis performed from a societal perspective and will only be
applicable to the Dutch healthcare system.
2.3.2.6. Index objective: molecular characterization (side-study). Due to
the rarity of the disease, little is known about molecular aberrations
related to urothelial carcinoma of the UUT and the prognostic proﬁle of
molecular alterations that correspond with or even might predict
bladder recurrences. In a time that cancers are increasingly stratiﬁed
by their molecular alterations and treatment decisions can be based
upon these alterations, it is important to investigate the genetic proﬁles
of urothelial carcinoma of the UUT. Sfakianos et al. compared the
genetic proﬁle of 59 high-grade urothelial carcinomas of the UUT with
another cohort of 102 high-grade UCB by targeted sequencing [28]. The
spectrum of genes mutated in tumors of the UUT and UCB was similar,
but the frequency of mutations in FGFR3, HRAS, TP53 and RB1 was not.
In high-grade urothelial carcinoma of the UUT FGFR3 and HRAS were
more frequently mutated, whereas mutations in TP53 and RB1 were less
prevalent compared to high-grade UCB. Most of the disparity in clinical
manifestation between urothelial carcinoma of the UUT and UCB may
result from anatomical diﬀerences because of the thinner smooth
muscle coﬀering the UUT, but Sfakianos et al. showed that there are
also genomic diﬀerences that might contribute to this phenomenon
[28]. These observations provide evidence that urothelial carcinoma of
the UUT and the bladder have distinct biological behaviors despite their
histopathological similarities and therefore might require
individualized treatment recommendations.
In both retrospective and prospective studies, a high proliferation
index as assessed by Ki-67 expression was associated with disease re-
currence and cancer-speciﬁc survival in urothelial carcinoma of the
UUT [29–33]. Furthermore, alterations in the mTOR-pathway, and the
genes HER2, BCAT1, CDCA5 and p53 might play a role in the prognosis
of high grade urothelial carcinoma of the UUT, but the impact of these
biomarkers hasn't been suﬃciently validated because of the small
portion of samples in single-institution cohorts [24].
Currently two hypotheses for the development of a bladder recur-
rence following RNU for urothelial carcinoma of the UUT are postu-
lated: a) intraluminal seeding and implantation of cancer cells [14,15];
multifocal tumors are descendants of a single transformed cell, which
proliferates and spreads by intraluminal seeding or intraepithelial
spread or b) in ﬁeld cancerization [34], where it is assumed that mul-
tiple cells become initiated or partially transformed as a result of car-
cinogenic hits. In order to address these hypotheses it is important to
compare the genomic proﬁle of the primary urothelial carcinoma of the
UUT and the subsequent bladder recurrence within the same patients.
Therefore, at inclusion, patients will be asked to provide separate
consent for the use of their tumor tissue for molecular analysis. DNA
will be isolated from the primary urothelial carcinoma of the UUT, the
bladder recurrence and a buccal swap or non-malignant kidney tissue.
Genomic sequencing will be performed to investigate tumor-speciﬁc
somatic mutations and copy number variations to compare the mole-
cular proﬁle of the primary urothelial carcinoma of the UUT and a
subsequent carcinoma of the bladder.
2.4. Sample size calculation
The estimated recurrence of urothelial carcinoma of the bladder
following RNU for a UUT urothelial carcinoma is based on the litera-
ture. It has been shown that in patients not treated with adjuvant in-
travesical therapy following RNU, the bladder recurrence rate at two
years was between 10 and 50% (mean 33.2%, total number of patients
reported 995, range 36–223) [10]. We hypothesize a reduction in the
risk of a bladder recurrence of 40% after RNU or partial ureterectomy
by the neoadjuvant regimen of a single instillation with chemotherapy
within 3 h before surgery. Consequently, this translates into a 19.9%
estimated bladder recurrence rate for this study. Therefore, it is cal-
culated that a sample size of 170 patients is needed to show a 40%
diﬀerence two years following surgery with a power of 80% using a
two-sided p-value of 0.05.
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2.5. Ethical approval
The study abides by the principles of the Declaration of Helsinki.
Ethical approval for this study was obtained from the institutional re-
view board of Erasmus University Medical Center Rotterdam (METC
2017–227, NL60919.078.17). Also the board of directors of all parti-
cipating hospitals have given permission for execution of this particular
trial.
3. Statistical analysis
All analyses are based on the intention-to-treat principle, i.e. all
eligible patients will be included in the analysis independently of
whether they received treatment or not. Data characterized by normal
distribution will be expressed as mean ± standard deviation.
Parameters not normally distributed will be expressed as median
(range).
3.1. Primary study parameter
The bladder relapse rate at two years following surgery is the pri-
mary endpoint of the study. The relapse rate will be compared with the
relapse rate of a matched historical cohort on a 1:2 basis (1 intervention
cohort:2 historical cohort). The historical cases will be selected by the
following criteria: age ≥18 years, treated by RNU or partial ureter-
ectomy for a histologically proven UUT urothelial carcinoma (cT1-T4
with or without CIS), no lymph node or distant metastasis at the mo-
ment of diagnosis as assessed by CT thorax-abdomen (cN0M0), a
minimum of two years of follow-up following surgery, no perioperative
systemic chemotherapy administered, and no history of urothelial
carcinoma of the urinary tract before diagnosis of the UUT urothelial
carcinoma. The diﬀerence in relapse rate between the intervention
cohort and the matched historical cohort will be assessed using a
multivariable Cox regression analysis and stratiﬁed by the following
confounders: age, type of surgery (RNU versus partial ureterectomy),
pathological stage, tumor grade, tumor size, tumor location, tumor
multiplicity, concomitant CIS, medical center of treatment and surgical
techniques (open versus laparoscopic).
3.2. Secondary study parameters
The diﬀerence in overall, cancer-speciﬁc and recurrence-free sur-
vival between the intervention cohort and matched historical cohort
will be estimated using a multivariable Cox regression analysis. The
toxicity of the treatment at diﬀerent time points will be tested using a
repeated measurements analysis. The quality of life at baseline, at 2
weeks and at 3 months following surgery will be compared using a
repeated measurements analysis. Furthermore, potential risk factors
will be identiﬁed using multivariable Cox proportional hazards. Co-
variables included in the analysis are: type of surgery (partial ureter-
ectomy or RNU (laparoscopic or open)), result of pre-operative urine
cytology, histological stage and grade of the tumor, tumor location,
concomitant CIS and lymph node involvement.
The primary economic analysis will be a cost-utility analysis per-
formed according to the Dutch guideline to determine whether
neoadjuvant intravesical instillations with Mitomycin before RNU or
organ sparing surgery are a cost-eﬀective alternative to the standard of
care (historical cohort) [35]. Additionally, a cost-eﬀectiveness analysis
will be conducted to determine the costs per prevented bladder recur-
rence. The time horizon will be from start of therapy (t= 0) till 24
months follow-up to take all relevant costs and eﬀects regarding the
MMC and standard of care strategy into account. The costs are deﬁned
as direct and indirect costs associated with procedures performed
within each regimen. The costs will be estimated by multiplying re-
source utilization with the cost per unit of resource (market prices,
guideline prices or self-determined prices based on costing methods, i.e.
full costing) [35]. The incremental cost-eﬀectiveness ratio (ICER) of
MMC will be calculated (i.e., the diﬀerence in costs of MMC versus
standard of care divided by the average change in QALYs and bladder
recurrence rate, respectively). The sensitivity of various costs per unit
of resource will be tested in sensitivity analyses.
All statistical analyses will be performed using statistics software
(SPSS version 21.0 for Windows, Chicago, IL, USA). A two-tailed p-
value of< 0.05 is considered signiﬁcant.
4. Study procedures
A ﬂow diagram of the REBACARE trial is presented in Appendix A.
The following procedures are performed for research purposes at a
diﬀerent time point or in addition to the standardized care.
4.1. Treatment
After consent is obtained for both the primary study and the side-
study, patients will be asked to provide a buccal swab for the collection
of germline DNA. On the day of surgery, MMC is administered in-
travesically in all patients within 3 h before surgery. The MMC is given
directly into the bladder by an indwelling catheter. The indwelling
catheter is inserted through the urethra and after instillation of the
MMC the catheter is clamped, which allows the medication to remain in
the bladder. The doses will be a suspension of 40mg MMC in 50ml
sterile saline (NaCl 0.9%) and must remain in the bladder for a period
of at least 1 h with a maximum of 2 h, if possible. The patient is then
transported to the operating room. Once the bladder is emptied by the
indwelling catheter, the bladder will be continuously rinsed with NaCl
0.9% to remove all remains of the MMC and possible ﬂoating tumor
cells. The indwelling catheter will remain inside the bladder during
surgery and the rinsing will be stopped at the moment the treating
surgeon is about to incise the bladder wall for excision of the ureteric
oriﬁce. The indwelling catheter will remain for some days after surgery
until the patient has recovered. The exact number of days the indwel-
ling catheter will remain in the bladder following surgery is at the
discretion of the treating physician. From a pilot experiment it is known
that neoadjuvantly administered intravesical MMC can no longer be
detected on the surgical equipment or inside the operating room once
the bladder is appropriately rinsed with 2× 50mL of NaCl 0,9% (per-
sonal communication by Dr. A.G.M. van der Heijden, MD PhD, Radboud
UMC). Therefore, medical personnel who will treat the study partici-
pants will not be exposed to MMC.
The surgical procedure is not performed for research purposes,
however the participating physicians will be asked to carry out the
procedures in a standardized matter; i.e. both the RNU or partial ur-
eterectomy must start with clipping of the ureter distal of the tumor
before manipulation of the ureter can take place. For a RNU, the ure-
teric oriﬁce must be circumcised and resected ‘en block’ attached to the
ureter (bladder cuﬀ). The pathology report must describe the presence
of the ureteral clip and, for the latter, the presence of a bladder cuﬀ
including the ureteric oriﬁce. The administration of antibiotic pro-
phylaxis is advocated and the antibiotic regimen (orally or in-
travenously) should be in accordance with the local guidelines of the
participating hospitals or based on a urinary culture.
4.2. Follow up
The follow up will be in line with the standardized care and will not
include additional investigations. Cystoscopy plus urine cytology will
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be performed at 3, 6, 12, 18 and 24 months. The follow-up also includes
CT-urography at 6, 12, 18, 24 months. In case of an invasive tumor,
follow-up will include a CT-thorax at 6 and 12 months. All patients will
complete two questionnaires at three moments during the study
(Appendix A) to examine the quality of life following this treatment. To
demonstrate side eﬀects, patients will ﬁll in a side-eﬀects form 4 times.
In case a bladder recurrence is suspected, it is warranted to take a di-
agnostic biopsy to histologically conﬁrm and classify urothelial carci-
noma of the bladder.
4.3. Side study: molecular analysis
Both a buccal swap and a biopsy of the tumor will be collected from
participants who provide separate informed consent. DNA will be iso-
lated from the primary UUT tumor, the subsequent intravesical recur-
rence and non-malignant kidney tissue or a buccal swab. Genomic se-
quencing will be performed to investigate tumor-speciﬁc somatic
mutations and copy number variations to compare the molecular proﬁle
of the primary UUT tumor and subsequent bladder tumor.
5. Discussion
5.1. Exposition of protocol
Following RNU for urothelial carcinoma of the UUT, the reported
recurrence rate of urothelial carcinoma in the bladder is 22–47% (4–7).
Intraluminal seeding [14,15] or in ﬁeld cancerization [34] are thought
to be the two hypotheses of this high recurrence rate. Based on the
assumption that intraluminal seeding has most of the impact on this
recurrence rate, a single postoperative instillation of chemotherapy
following RNU has been introduced, and has shown to decrease the risk
of bladder recurrence by 52% (relative risk reduction) [10]. Given the
fact that many treating physicians waive the addition of a postoperative
instillation with chemotherapy following RNU or partial ureterectomy,
despite recommendation by the EAU guideline [2], this could be an
indication that another (neo)adjuvant treatment is desirable. To avoid
the limitations in current treatment protocols of urothelial carcinoma of
the UUT, the REBACARE trial will be the ﬁrst prospective trial that
could change current management. The fact that intravesical instilla-
tion will be administered before surgery makes this study unique and
plausible positive for the compliance rate.
The REBACARE trial has additional aims besides the reduction of a
subsequent bladder recurrence and a safer toxicity proﬁle in compar-
ison with a postoperative instillation, since the study also aims to ex-
plore the genetic proﬁle of urothelial carcinoma of the UUT in more
detail within a side-study performed during the REBACARE-trial. This is
of speciﬁc interest, in a time in which the decision of certain treatment
modalities of various tumors does not only rely on clinicopathological
characteristics, but can possibly also rely on tumor-speciﬁc molecular
alterations. Furthermore, molecular characterization may reveal tumor-
speciﬁc alterations that are targets for new anticancer therapies. More
important, by performing a molecular comparison of the primary UUT
tumor and a subsequent bladder recurrence, the hypothesis that in-
traluminal seeding is responsible for developing bladder recurrences
can be explored. If this is the case, tumors of both the UUT and the
subsequent bladder tumor should have identical molecular alterations,
i.e. tumor-speciﬁc mutations. On the other hand Sfakianos et al. showed
diﬀerences in the genetic proﬁles and mutational status between
urothelial carcinoma of the UUT and UCB [28]. Although these al-
terations were not examined within the same patient, their ﬁndings
support the hypothesis that subsequent bladder tumors are de novo
primary tumors with speciﬁc molecular alterations. Lastly, a molecular
comparison of the primary UUT of the patients who develop a recur-
rence versus those who do not might reveal important aberrations that
could explain the risk of the development of a bladder recurrence or
might even be predictive of a bladder cancer recurrence. The RE-
BACARE trial is one of the ﬁrst studies in which DNA from the primary
tumor as well as DNA from the bladder recurrence of the same patient
will be compared and this will result in unique information.
5.2. Study limitations
There are several limitations associated with the design of the study.
Theoretically, the REBACARE trial could be designed as a prospective
randomized controlled trial generating level 1 evidence. However, a
randomized controlled trial would not be feasible due to the large
number of study participants in relation to the relative low number of
patients that will be diagnosed and treated for urothelial carcinoma of
the UUT. In addition, due to the low compliance rate for a postoperative
instillation with chemotherapy, inclusion of patients in the post-op-
erative instillation arm (standard of care) will take very long.
Furthermore, the recommendation in the EAU guideline for a post-
operative instillation of chemotherapy following RNU makes it not
ethical to conduct a study in which any form of intravesical instillation
with chemotherapy is withholded in the control arm.
The exclusion criteria of a previous UCB will limit the inclusion rate
of the REBACARE trial as the majority of patients with urothelial car-
cinoma of the UUT are known to have had one or more episodes of UCB
in their history. However, this was necessary, because it is known that
these patients are at much higher risk to develop a subsequent bladder
recurrence following surgery for urothelial carcinoma of the UUT
[11,24,36]. Including these patients will potentially jeopardize the
outcome of this trial because it will have an impact on the primary
endpoint of this trial.
6. Conclusion
Approximately 40% of patients will develop an intravesical recur-
rence following a RNU for urothelial carcinoma of the UUT. A single
postoperative instillation with chemotherapy reduces the risk of a
bladder cancer recurrence signiﬁcantly. Nevertheless, the compliance
rate of clinicians with a single postoperative instillation is low due to
the potential risk of extravasation of chemotherapy. The REBACARE
trial is the ﬁrst prospective trial that aims to determine the eﬀect of a
single preoperative intravesical instillation with chemotherapy on the
risk of a bladder cancer recurrence following RNU for urothelial car-
cinoma of the UUT. This change in order of treatment may prove to be
equally eﬀective as a postoperative instillation but with a safer proﬁle
and has the potential to change clinical practice in a deﬁnitive way.
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Appendix A. Flow-chart of the REBACARE trial.
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Appendix B. In- and exclusion criteria of the REBACARE trial.
Inclusion
criteria
1. Histologically proven urothelial carcinoma of the UUT with or without concurrent carcinoma in situ (CIS only is also allowed)
or patients with a suspicion of a urothelial carcinoma of the UUT on CT-scan plus a urinary cytology sample showing high-grade
urothelial carcinoma;
2. Patients planned to be treated either by partial ureterectomy or by a radical nephro-ureterectomy (open or laparoscopic)
including a bladder cuﬀ;
3. Age ≥18 years;
4. WHO performance status 0, 1 or 2;
5. Negative pregnancy test in woman with childbearing potential;
6. Written informed consent.
Exclusion
criteria
1. If pre-operative histology by biopsy: aberrant histology of the UUT tumor of> 50% (adenocarcinoma, small cell carcinoma,
squamous cell carcinoma).
2. History or presence of a malignant tumor or carcinoma in situ of the bladder.
3. History of UUT urothelial carcinoma on the contralateral side or presence of bilateral UUT urothelial carcinoma.
4. Known allergy against Mitomycin.
5. Anticipated adjuvant intravesical treatment with chemo- or immunotherapy.
6. Acute urinary tract infection at the time of inclusion as assessed by urinary culturing.
7. Lymphadenopathy or distant metastases as assessed by preoperative CT-scan of thorax and abdomen.
8. Any other concurrent severe or uncontrolled disease preventing the safe administration of intravesical Mitomycin.
9. Breastfeeding women.
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